Drug intelligence / Profile preview

GT201 + teraplizumab

Development stage: Unknown
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (presumed)

Overview

GT201 + teraplizumab is a combination therapy consisting of two investigational monoclonal antibodies. GT201 is not well-documented in the current literature or clinical trial registries as of June 2025, and its specific target and mechanism are unclear. Teraplizumab also does not appear in major drug databases or published studies under this name; it may be a typographical error or an experimental agent with limited public information. No evidence was found for this exact combination being studied together in clinical trials, nor for either component as an approved pharmaceutical product.

Targets

CD3E (T-cell surface glycoprotein CD3 epsilon chain)IL-6R (Interleukin-6 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on GT201 + teraplizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT201 + teraplizumab.

Explore the full profile